<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    7370875
   </pmid>
   <datecreated>
    <year>
     1980
    </year>
    <month>
     07
    </month>
    <day>
     28
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1980
    </year>
    <month>
     07
    </month>
    <day>
     28
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0008-4409
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       122
      </volume>
      <issue>
       8
      </issue>
      <pubdate>
       <year>
        1980
       </year>
       <month>
        Apr
       </month>
       <day>
        19
       </day>
      </pubdate>
     </journalissue>
     <title>
      Canadian Medical Association journal
     </title>
     <isoabbreviation>
      Can Med Assoc J
     </isoabbreviation>
    </journal>
    <articletitle>
     Hypokalemia during the treatment of arterial hypertension with diuretics.
    </articletitle>
    <pagination>
     <medlinepgn>
      905-7
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      In a study of 50 patients with uncomplicated arterial hypertension the administration of hydrochlorothiazide, 50 to 100 mg daily or every other day, with or without reserpine, 0.25 mg daily, resulted in a fall in the mean blood pressure from 182/113 to 144/92 mm Hg. The mean duration of therapy was 19 months. The mean serum potassium concentration was 4.3 mmol/l before the onset of therapy. It fell during the first 6 weeks of treatment, but seldom below 3.5 mmol/l, then rose gradually and spontaneously to 4.1 mmol/l after 19 months of therapy. All the patients remained asymptomatic. These findings bring into question the routine use of potassium supplements or a potassium-sparing diuretic, such as spironolactone or triamterene, during the treatment of hypertension with diuretics such as the thiazides. The use of potassium supplements or a potassium-sparing agent may induce hyperkalemia in spite of the simultaneous administration of a diuretic that acts more proximally. Since hyperkalemia is potentially lethal, the serum potassium concentration should be carefully monitored in any patient receiving potassium supplements or a potassium-sparing agent.
     </abstracttext>
    </abstract>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Lemieux
      </lastname>
      <forename>
       G
      </forename>
      <initials>
       G
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Beauchemin
      </lastname>
      <forename>
       M
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Vinay
      </lastname>
      <forename>
       P
      </forename>
      <initials>
       P
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Gougoux
      </lastname>
      <forename>
       A
      </forename>
      <initials>
       A
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     CANADA
    </country>
    <medlineta>
     Can Med Assoc J
    </medlineta>
    <nlmuniqueid>
     0414110
    </nlmuniqueid>
    <issnlinking>
     0008-4409
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Bicarbonates
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      50-55-5
     </registrynumber>
     <nameofsubstance>
      Reserpine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      58-93-5
     </registrynumber>
     <nameofsubstance>
      Hydrochlorothiazide
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      7440-09-7
     </registrynumber>
     <nameofsubstance>
      Potassium
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      Can Med Assoc J. 1978 May 6;118(9):1074-8
     </refsource>
     <pmid version="1">
      25707
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Can Med Assoc J. 1977 Jan 22;116(2):173-6
     </refsource>
     <pmid version="1">
      343894
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Can Med Assoc J. 1978 Jun 24;118(12):1513-8
     </refsource>
     <pmid version="1">
      657047
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Kidney Int. 1977 Jun;11(6):505-15
     </refsource>
     <pmid version="1">
      875266
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      N Engl J Med. 1972 Nov 23;287(21):1074-81
     </refsource>
     <pmid version="1">
      4404062
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1975 Apr 5;1(7910):759-62
     </refsource>
     <pmid version="1">
      47997
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1974 Nov 4;230(5):743-8
     </refsource>
     <pmid version="1">
      4479242
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1973 Jul 2;225(1):40-3
     </refsource>
     <pmid version="1">
      4740303
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Metabolism. 1970 Jan;19(1):58-70
     </refsource>
     <pmid version="1">
      5410663
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Intern Med. 1966 Sep;65(3):521-7
     </refsource>
     <pmid version="1">
      5911746
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bicarbonates
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Therapy, Combination
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hydrochlorothiazide
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypertension
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypokalemia
     </descriptorname>
     <qualifiername majortopicyn="Y">
      chemically induced
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Monitoring, Physiologic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Potassium
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Reserpine
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC1801652
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1980
     </year>
     <month>
      4
     </month>
     <day>
      19
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1980
     </year>
     <month>
      4
     </month>
     <day>
      19
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1980
     </year>
     <month>
      4
     </month>
     <day>
      19
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     7370875
    </articleid>
    <articleid idtype="pmc">
     PMC1801652
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

